MEET YOUR NEW NEIGHBORSNeighborhood is a community of entrepreneurs, innovators, regulatory experts, health tech consultants and industry KOLs working together to accompany health tech startups to their next significant valuation milestones.
Cardiology, neurology, stroke
Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide.
Op2lysis program aims at demonstrating the clinical efficacy and safety of its therapeutic solution to be ready to enter advanced phases of development by 2023.
Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of thrombolytic treatment in stroke, the first cause of acquired disability worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.
Technion – Israel Institute of Technology
The Technion – Israel Institute of Technology is a public research university in Haifa, Israel. Established in 1968, the Faculty of Biomedical Engineering has a multidiciplinary scope nurturing research activities that blend medical and biological engineering. Research projects have resulted in the development of patented medical aids. Recent research breakthroughs include the identification of a structured neurological code for syllables and could let paraplegics "speak" virtually through the connection of the brain to a computer.
Pharmacodynamic Modeling and Artificial Intelligence
Hillo develops the first AI-based decision support platform for diabetic patients, based on a blood glucose levels predictive system that adapts to every patient’s physiology and habits. Our technology combines pharmacodynamic modeling and artificial intelligence, we develop tools for patients to help them anticipate and avoid hypo- or hyperglycemia, and for care teams to help them understand each patient’s specific glycemic response. We’ve demonstrated outstanding results and accuracy of our predictive technology through trials in hospitals.
OP2 Drugs SAS (“OP2″) is a biotech company that aims at developing innovative life-saving drugs for unmet medical needs, especially in the cardiology field. Our first patented compound, OP2113, which targets mitochondrial dysfunction, is in preclinical stage, with a strong scientific rational.
Based on strategic partnerships in Europe and in the US, we are generatling growth and value for all stakeholders thanks to our drug candidates pipeline, in several indications. OP2 is planned to move forward to clinic in 2018.
Located in Pessac, close to Bordeaux (France), OP2 Drugs is supported by Unitec (Bordeaux), managed by Frédéric Marin (CEO) and Nicolas Pineau (COO), and funded by ambitious financial players.
Neurodegenerative and (auto)-immune diseases
Today, Encefa has its Lead, an optimized humanized mAb with its efficacy validated in 3 different mice models and showing a low toxicity profile, ready to enter its preclinical development phase.
The objective of this project is to make catheters activatable to improve their navigation capabilities and to speed up the speed of treatment placement while ensuring the safety of the procedure during the intervention.
The platform integrates outputs of specialized medical devices and algorithms developed in collaboration with medical R&D centers.
LE HUB BPI FRANCE – HEALTHTECH
Pour accompagner les startups de la santé (biotech, medtech et e-santé), Bpifrance lance un nouvel accélérateur et dévoile la première promotion. Le Hub HealthTech vise à mieux connecter les entreprises du secteur à leur écosystème pour favoriser leur croissance et leur développement.
L’accélérateur HealthTech du Hub se focalise sur l’accompagnement des participations biotech, medtech et e-santé en post-amorçage de Bpifrance en leur proposant un programme sur-mesure, adapté aux problématiques propres au secteur (temps de développement, problématiques réglementaires, besoins capitalistiques, etc.).